Eucrisa: a New Treatment for Atopic Dermatitis
If you suffer from the pain and discomfort of atopic dermatitis, we know how frustrating it can be to find relief. That’s why we’re excited to tell you about a new treatment that’s recently been approved by the FDA: Eucrisa.
The discomfort of atopic dermatitis
According to the National Eczema Association, approximately 18 million Americans have some form of atopic dermatitis, a chronic inflammatory skin disease characterized by a red, itchy rash that usually appears on the cheeks, arms, or legs. Flare-ups often recur over the course of one’s life, and intense repeated scratching leads to swelling, cracking, and even a permanent thickening of the skin. Severe cases can cause open, weeping sores and serious skin infections. The worst part is, there’s no known cure – only temporary relief from the discomfort.
Problems with old methods of treatment for atopic dermatitis
Atopic dermatitis can be an extremely difficult condition to treat effectively. Topical corticosteroids are the most commonly used treatment because of their ability to control itching and inflammation. But unfortunately, the effectiveness of topical corticosteroids can wear off over time as the body builds up a resistance to the medication. Extended use can also cause harmful side effects like thinning of the skin, stretch marks, or enlarged blood vessels.
Oral steroids and antihistamines can help alleviate the pain, but it’s usually an uncomfortable game of trial and error to find out which one works – and even when a successful therapy is found, its effects are often only temporary.
Why Eucrisa is a revolutionary for atopic dermatits
The introduction of Eucrisa marks the first non-steroidal treatment for atopic dermatitis to be approved by the FDA in over 10 years. It works by inhibiting a common enzyme that causes inflammation, providing relief from the intense itching and swelling that accompanies atopic dermatitis. Patients who’ve used Eucrisa have experienced long-lasting results – without the harmful side effects of steroids.
How Eucrisa was approved through dermatology clinical research trials
The process of getting Eucrisa out into the marketplace involved a series of placebo-controlled clinical trials with over 1,500 participants, all of whom suffered from mild to moderate atopic dermatitis. Within 28 days, most of the trial participants enjoyed clear skin and relief from the intense itching of their condition. By taking part in this clinical trial, these participants gained access to Eucrisa before the general public, making them the first people in the world to reap the immense benefits of this revolutionary treatment.
Gain access to cutting-edge dermatology treatment at CDCRI in San Diego
This kind of innovative work is what we do at the California Dermatology and Clinical Research Institute. By working closely with pharmaceutical companies, we’re able to bring the latest and greatest medications to our patients, long before the general public. By participating in a clinical trial, not only you could get access to cutting-edge therapies for atopic dermatitis, but you’ll also have the satisfaction of knowing that you’re helping the medical community bring new treatments to the millions of people who are in need of relief.
There are many new treatments on the horizon for atopic dermatitis. If you want to get in on the ground floor, call us at (760) 203-3389 to see if you qualify to participate in one of our many clinical trials.